Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?

European Journal of Cancer

Volumn 45, Issue 9, 2009, Pages 1649-1653

  Parkin, Donald Maxwell ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Hormone replacement therapy; Incidence; Trends; UK

Indexed keywords

ESTROGEN; GESTAGEN; SEX HORMONE; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; UNITED KINGDOM;

AGE DISTRIBUTION; AGE OF ONSET; AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE;

EID: 65849120565     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.016     Document Type: Article

References (20)

1. Watson J., Wise L., and Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63 (2007) 843-849
2. In: Smith A. (Ed). IARC monographs on the evaluation of carcinogenic risks to humans. Hormonal contraception and post-menopausal hormonal therapy vol. 72 (1999), IARC, Lyon
3. Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer 44 (2008) 2344-2349
4. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med 356 (2007) 1670-1674
5. Jemal A., Ward E., and Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 9 3 (2007) R28
6. Glass A.G., Lacey Jr. J.V., Carreon J.D., and Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99 (2007) 1152-1161
7. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
8. General Practice Research database (GPRD) .
9. Beral V. Million women study collaborators breast cancer and hormone-replacement therapy in the million women study. Lancet 362 (2003) 419-427
10. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 10 (2008) 1345-1389
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350 (1997) 1047-1059
12. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al., WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomised trial. JAMA 289 (2003) 3243-3253
13. Robbins A.S., and Clarke C.A. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25 (2007) 3437-3439
14. Paci E., and Duffy S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res 7 (2005) 266-270
15. Seppanen J., Heinavaara S., Anttila A., Sarkeala T., Virkkunen H., and Hakulinen T. Effects of different phases of an invitational screening program on breast cancer incidence. Int J Cancer 119 (2006) 920-924
16. Department of Health. Health care statistics. Breast cancer screening programme, England. ; 2007b.
17. Blanks R.G., Bennett R.L., Patnick J., et al. The effect of changing from one to two views at incident (subsequent) screens in the NHS breast screening programme in England: impact on cancer detection and recall rates. Clin Radiol 60 (2005) 674-680
18. Canfell K., Banks E., Moa A.M., and Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188 (2008) 641-644
19. Katalinic A., and Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107 (2008) 427-430
20. Soerjomataram I., Coebergh J.W., Louwman M.W., Visser O., and van Leeuwen F.E. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol 25 31 (2007) 5038-5039